{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:05:50Z","timestamp":1778706350645,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006676","name":"Lilly Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06915-3","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:10:13Z","timestamp":1773367813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology, treatment patterns, and survival outcomes of patients with mantle cell lymphoma in Germany: a retrospective analysis of administrative claims data"],"prefix":"10.1007","volume":"105","author":[{"given":"Heiko","family":"Friedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Hennies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Zschocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Khageh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"B\u00f6lz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Bocuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okan","family":"Zaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"6","key":"6915_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M (2019) Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 94(6):710\u2013724. https:\/\/doi.org\/10.1002\/ajh.25487","journal-title":"Am J Hematol"},{"issue":"5","key":"6915_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/03007995.2020.1742101","volume":"36","author":"N Monga","year":"2020","unstructured":"Monga N, Garside J, Quigley J, Hudson M, O\u2019Donovan P, O\u2019Rourke J, Tapprich C, Parisi L, Davids MS, Tam C (2020) Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin 36(5):843\u2013852. https:\/\/doi.org\/10.1080\/03007995.2020.1742101","journal-title":"Curr Med Res Opin"},{"key":"6915_CR3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, Klapper W, Hermine O et al (2014) Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 32:1338\u20131346. https:\/\/doi.org\/10.1200\/JCO.2013.52.2466","journal-title":"J Clin Oncol"},{"issue":"suppl4","key":"6915_CR4","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilerg O, Walewski J, Ladetoo M, ESMO Guidelines Committee (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl4):iv62\u2013iv71. https:\/\/doi.org\/10.1093\/annonc\/mdx223","journal-title":"Ann Oncol"},{"issue":"7","key":"6915_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"11","key":"6915_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR et al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140(11):1229\u20131253. https:\/\/doi.org\/10.1182\/blood.2022015851","journal-title":"Blood"},{"issue":"Suppl 1","key":"6915_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hon.3149","volume":"41","author":"E Silkenstedt","year":"2023","unstructured":"Silkenstedt E, Dreyling M (2023) Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches. Hematol Oncol 41(Suppl 1):36\u201342. https:\/\/doi.org\/10.1002\/hon.3149","journal-title":"Hematol Oncol"},{"issue":"1","key":"6915_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","volume":"182","author":"P McKay","year":"2018","unstructured":"McKay P, Leach M, Jackson B, Robinson S, Rule S (2018) Guideline for the management of mantle cell lymphoma. Br J Haematol 182(1):46\u201362. https:\/\/doi.org\/10.1111\/bjh.15283","journal-title":"Br J Haematol"},{"key":"6915_CR9","unstructured":"National Comprehensive Cancer Network (2021) NCCN guidelines for patients. mantle cell lymphoma. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/Mantle-patient-guideline.pdf. Accessed 26 May 2022"},{"issue":"9","key":"6915_CR10","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/healthcare10091682","volume":"10","author":"D Horgan","year":"2022","unstructured":"Horgan D, Walewski J, Aurer I, Visco C, Gine E, Fetica B, Jerkeman M, Kozaric M, Gomes da Silva M, Dreyling M (2022) Tackling mantle cell lymphoma in Europe. Healthc (Basel) 10(9):1682. https:\/\/doi.org\/10.3390\/healthcare10091682","journal-title":"Healthc (Basel)"},{"issue":"1","key":"6915_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","volume":"82","author":"S Cortelazzo","year":"2012","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M (2012) Mantle cell lymphoma. Crit Rev Oncol Hematol 82(1):78\u2013101. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.05.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"6915_CR12","unstructured":"onkopedia (2023) Mantelzell-Lymphom. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/mantelzell-lymphom\/@@guideline\/html\/index.html. Accessed 15 March 2025"},{"key":"6915_CR13","unstructured":"Janssen-Cilag International NV (n.d.) Summary of product characteristics: imbruvica. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_el.pdf. Accessed 30 June 2025"},{"issue":"8","key":"6915_CR14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","volume":"32","author":"S Rule","year":"2018","unstructured":"Rule S, Jurczak W, Jerkeman M et al (2018) Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 32(8):1799\u20131803. https:\/\/doi.org\/10.1038\/s41375-018-0023-2","journal-title":"Leukemia"},{"issue":"12","key":"6915_CR15","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","volume":"5","author":"CS Tam","year":"2021","unstructured":"Tam CS, Opat S, Simpson D et al (2021) Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 5(12):2577\u20132585. https:\/\/doi.org\/10.1182\/bloodadvances.2020004074","journal-title":"Blood Adv"},{"issue":"6","key":"6915_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"M Wang","year":"2013","unstructured":"Wang M, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"6","key":"6915_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P et al (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739\u2013745. https:\/\/doi.org\/10.1182\/blood-2015-03-635326","journal-title":"Blood"},{"issue":"10121","key":"6915_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL et al (2018) Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391(10121):659\u2013667. https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2","journal-title":"Lancet"},{"issue":"11","key":"6915_CR19","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML (2016) Mantle cell lymphoma. J Clin Oncol 34(11):1256\u20131269. https:\/\/doi.org\/10.1200\/JCO.2015.63.5904","journal-title":"J Clin Oncol"},{"issue":"12","key":"6915_CR20","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P et al (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799\u20131807. https:\/\/doi.org\/10.1182\/bloodadvances.2018028761","journal-title":"Blood Adv"},{"issue":"4","key":"6915_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF et al (2017) Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a real world study. Hematol Oncol 35(4):528\u2013535. https:\/\/doi.org\/10.1002\/hon.2380","journal-title":"Hematol Oncol"},{"issue":"12","key":"6915_CR22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP et al (2016) Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127(12):1559\u20131563. https:\/\/doi.org\/10.1182\/blood-2015-10-673145","journal-title":"Blood"},{"issue":"4","key":"6915_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S et al (2018) Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578\u2013587. https:\/\/doi.org\/10.1111\/bjh.15567","journal-title":"Br J Haematol"},{"issue":"2","key":"6915_CR24","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S et al (2019) Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 104(2):e68\u2013e71. https:\/\/doi.org\/10.3324\/haematol.2018.198812","journal-title":"Haematologica"},{"issue":"3","key":"6915_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G et al (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145(3):344\u2013349. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07626.x","journal-title":"Br J Haematol"},{"issue":"4","key":"6915_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA et al (2020) Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol 189(4):684\u2013688. https:\/\/doi.org\/10.1111\/bjh.16416","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"6915_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2021-148949","volume":"138","author":"T Phillips","year":"2021","unstructured":"Phillips T, Dickinson M, Morschhauser F et al (2021) Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R\/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton\u2019s tyrosine kinase inhibitor (BTKi) therapy. Blood 138(Suppl 1):130. https:\/\/doi.org\/10.1182\/blood-2021-148949","journal-title":"Blood"},{"issue":"1","key":"6915_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","volume":"10","author":"M Wang","year":"2017","unstructured":"Wang M, Schuster SJ, Phillips T et al (2017) Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004). J Hematol Oncol 10(1):171. https:\/\/doi.org\/10.1186\/s13045-017-0537-5","journal-title":"J Hematol Oncol"},{"issue":"14","key":"6915_CR29","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"6915_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1182\/blood-2021-148607","volume":"138","author":"M Wang","year":"2021","unstructured":"Wang M, Mei M, Barr PM et al (2021) Phase 1 dose escalation and cohort expansion study of the anti-ROR1 antibody-drug conjugate Zilovertamab Vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma. Blood 138(Suppl 1):528\u2013530. https:\/\/doi.org\/10.1182\/blood-2021-148607","journal-title":"Blood"},{"issue":"6","key":"6915_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L et al (2020) Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623\u2013629. https:\/\/doi.org\/10.1002\/ajh.25796","journal-title":"Am J Hematol"},{"issue":"4","key":"6915_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/bjh.18519","volume":"202","author":"G Hess","year":"2023","unstructured":"Hess G, Dreyling M, Oberic L et al (2023) Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 202(4):749\u2013759. https:\/\/doi.org\/10.1111\/bjh.18519","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"6915_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1182\/blood-2021-149138","volume":"138","author":"M Wang","year":"2021","unstructured":"Wang M, Shah NN, Alencar AJ et al (2021) Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1\/2 BRUIN study. Blood 138(Suppl 1):381. https:\/\/doi.org\/10.1182\/blood-2021-149138","journal-title":"Blood"},{"issue":"10277","key":"6915_CR34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Cheah CY et al (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397(10277):892\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)00224-5","journal-title":"Lancet"},{"issue":"10441","key":"6915_CR35","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E et al (2024) Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403(10441):2293\u20132306. https:\/\/doi.org\/10.1016\/S0140-6736(24)00184-3","journal-title":"Lancet"},{"key":"6915_CR36","doi-asserted-by":"publisher","first-page":"12302","DOI":"10.3389\/jpps.2024.12302","volume":"27","author":"K Zisis","year":"2024","unstructured":"Zisis K, Pavi E, Geitona M, Athanasakis K (2024) Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. J Pharm Pharm Sci 27:12302. https:\/\/doi.org\/10.3389\/jpps.2024.12302","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"6915_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpt.2449","volume":"111","author":"D McNair","year":"2022","unstructured":"McNair D, Lumpkin M, Kern S, Hartman D (2022) Use of RWE to Inform regulatory, public health policy, and intervention priorities for the developing world. Clin Pharmacol Ther 111(1):44\u201351. https:\/\/doi.org\/10.1002\/cpt.2449","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"6915_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/pds.1721","volume":"18","author":"F Hoffmann","year":"2009","unstructured":"Hoffmann F (2009) Review on use of German health insurance medication claims data for epidemiological research. Pharmacoepidemiol Drug Saf 18(5):349\u2013356. https:\/\/doi.org\/10.1002\/pds.1721","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"6915_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10198-016-0849-3","volume":"18","author":"S Neubauer","year":"2017","unstructured":"Neubauer S, Kreis K, Klora M, Zeidler J (2017) Access, use, and challenges of claims data analyses in Germany. Eur J Health Econ 18(5):533\u2013536. https:\/\/doi.org\/10.1007\/s10198-016-0849-3","journal-title":"Eur J Health Econ"},{"issue":"2","key":"6915_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healthpol.2016.01.007","volume":"120","author":"K Kreis","year":"2016","unstructured":"Kreis K, Neubauer S, Klora M, Lange A, Zeidler J (2016) Status and perspectives of claims data analyses in Germany-A systematic review. Health Policy 120(2):213\u2013226. https:\/\/doi.org\/10.1016\/j.healthpol.2016.01.007","journal-title":"Health Policy"},{"issue":"10097","key":"6915_CR41","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse R, Blumel M, Knieps F, Barnighausen T (2017) Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet 390(10097):882\u2013897. https:\/\/doi.org\/10.1016\/S0140-6736(17)31280-1","journal-title":"Lancet"},{"key":"6915_CR42","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00103-008-0644-0","volume":"51","author":"I Schubert","year":"2008","unstructured":"Schubert I, K\u00f6ster I, K\u00fcpper-Nybelen J, Ihle P (2008) Versorgungsforschung mit GKV- Routinedaten. Bundesgesundheitsbl 51:1095\u20131105. https:\/\/doi.org\/10.1007\/s00103-008-0644-0","journal-title":"Bundesgesundheitsbl"},{"key":"6915_CR43","volume-title":"Routinedaten im Gesundheitswesen. Handbuch Sekund\u00e4rdatenanalyse: Grundlagen, Methoden undPerspektiven","author":"E Swart","year":"2014","unstructured":"Swart E, Ihle P, Gothe H et al (2014) Routinedaten im Gesundheitswesen. Handbuch Sekund\u00e4rdatenanalyse: Grundlagen, Methoden undPerspektiven, 2nd edn. Huber, Bern","edition":"2"},{"key":"6915_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11553-022-00968-8","author":"I Schubert","year":"2022","unstructured":"Schubert I (2022) Arzneimittelepidemiologie und Arzneimittelverbrauchsforschung auf der Basis von Krankenkassendaten: zentrale Untersuchungsfragen und methodische Hinweise [Drug epidemiology and drug utilisation research based on health insurance data: Central research questions and methodological notes]. Pr\u00e4v Gesundheitsf. https:\/\/doi.org\/10.1007\/s11553-022-00968-8","journal-title":"Pr\u00e4v Gesundheitsf"},{"key":"6915_CR45","unstructured":"GKV (2024) [if gte mso 9]> Normal 0 false false false false EN-GB JA AR-SA GKV und PKV \u2013 Mitglieder \u2013 und Versichertenzahl im Vergleich bisStatista 2024. https:\/\/de.statista.com\/statistik\/daten\/studie\/155823\/umfrage\/gkv-pkv-mitglieder-und-versichertenzahl-im-vergleich\/.\u00a0Accessed 15 Mar 2025"},{"issue":"5","key":"6915_CR46","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"R Jain","year":"2022","unstructured":"Jain R, Wang ML (2022) Mantle cell lymphoma in 2022\u2014A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97(5):638\u2013656. https:\/\/doi.org\/10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"issue":"8","key":"6915_CR47","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN et al (2014) Real-world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 124(8):1288\u20131295. https:\/\/doi.org\/10.1182\/blood-2014-03-559930","journal-title":"Blood"},{"issue":"8","key":"6915_CR48","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3109\/10428194.2012.760041","volume":"54","author":"B Aschebrook-Kilfoy","year":"2013","unstructured":"Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, Smith SM, Chiu BC (2013) An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma 54(8):1677\u20131683. https:\/\/doi.org\/10.3109\/10428194.2012.760041","journal-title":"Leuk Lymphoma"},{"key":"6915_CR49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1182\/asheducation-2016.1.425","volume":"1","author":"P Soubeyran","year":"2016","unstructured":"Soubeyran P, Gressin R (2016) Treatment of the elderly patient with mantle cell lymphoma. Hematol Am Soc Hematol Educ Program 1:425\u2013431. https:\/\/doi.org\/10.1182\/asheducation-2016.1.425","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6915_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41408-024-01204-6","volume":"14","author":"S Pahnke","year":"2024","unstructured":"Pahnke S, Abalo KD, Ekberg S, Albertsoon-Lindblad A, Smedby KE, Jerkeman M, Glimeliius I (2024) Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older. Blood Cancer J 14:222. https:\/\/doi.org\/10.1038\/s41408-024-01204-6","journal-title":"Blood Cancer J"},{"issue":"1","key":"6915_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bjh.18597","volume":"201","author":"M Harmanen","year":"2023","unstructured":"Harmanen M, Hujo M, Sund R et al (2023) Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. Br J Haematol 201(1):64\u201374. https:\/\/doi.org\/10.1111\/bjh.18597","journal-title":"Br J Haematol"},{"issue":"31","key":"6915_CR52","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.21.00693","volume":"39","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, Nanthakumar K, Calvillo-Arguelles O, Lee DS, Thavendiranathan P (2021) Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: A population-based cohort study. J Clin Oncol 39(31):3453\u20133462. https:\/\/doi.org\/10.1200\/JCO.21.00693","journal-title":"J Clin Oncol"},{"issue":"14","key":"6915_CR53","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","volume":"6","author":"M Narkhede","year":"2022","unstructured":"Narkhede M, Goyal G, Shea L, Mehta A, Giri S (2022) Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv 6(14):4122\u20134131. https:\/\/doi.org\/10.1182\/bloodadvances.2022007247","journal-title":"Blood Adv"},{"key":"6915_CR54","doi-asserted-by":"publisher","first-page":"8262787","DOI":"10.1155\/2022\/8262787","volume":"2022","author":"LM Hess","year":"2022","unstructured":"Hess LM, Chen Y, Abada PB, Konig H, Walgren RA (2022) Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: A real-world electronic medical records study. Adv Hematol 2022:8262787. https:\/\/doi.org\/10.1155\/2022\/8262787","journal-title":"Adv Hematol"},{"issue":"10","key":"6915_CR55","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1007\/s12325-022-02258-3","volume":"39","author":"S Rai","year":"2022","unstructured":"Rai S, Tanizawa Y, Cai Z, Huang Y-J, Taipale K, Tajimi M (2022) Outcomes for recurrent mantle cell lymphoma post-ibrutinib therapy: a retrospective cohort study from a Japanese administrative database. Adv Ther 39(10):4792\u20134807. https:\/\/doi.org\/10.1007\/s12325-022-02258-3","journal-title":"Adv Ther"},{"key":"6915_CR56","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.clml.2018.07.081","volume":"18","author":"BJGE Brandhuber","year":"2018","unstructured":"Brandhuber BJGE, Smith S (2018) LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk 18:S216. https:\/\/doi.org\/10.1016\/j.clml.2018.07.081","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6915_CR57","unstructured":"Eli Lilly Nederland B.V (n.d.) Summary of Product Characteristics: Jaypirca. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jaypirca-epar-product-information_en.pdf. Accessed 30 June 2024"},{"key":"6915_CR58","doi-asserted-by":"publisher","first-page":"204062072210807","DOI":"10.1177\/20406207221080738","volume":"13","author":"B Tbakhi","year":"2022","unstructured":"Tbakhi B, Reagan PM (2022) Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Ther Adv Hematol 13:20406207221080738. https:\/\/doi.org\/10.1177\/20406207221080738","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"6915_CR59","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","volume":"6","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni G, Rejeski K, Villacampa G et al (2022) Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 6(12):3606\u20133610. https:\/\/doi.org\/10.1182\/bloodadvances.2021006922","journal-title":"Blood Adv"},{"key":"6915_CR60","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL et al (2023) Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 41:3988\u20133997. https:\/\/doi.org\/10.1200\/JCO.23.00562","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"6915_CR61","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood-2024-200735","volume":"144","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn JK, Gine E et al (2024) Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the Randomized Triangle Trial by the European MCL Network. Blood 144(Suppl 1):240. https:\/\/doi.org\/10.1182\/blood-2024-200735","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06915-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:06Z","timestamp":1776405546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06915-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6915"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06915-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was not required since it was based on anonymized claims data. The health insurance companies were informed about the study, and the necessary approvals were granted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Heiko Friedel is an employee of Team Gesundheit, who was contracted by Eli Lilly to conduct the data analysis. Christian Buske has received honoraria from Roche\/Genentech, Janssen, BeiGene, Novartis, Pfizer, Incyte, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron, Sobi, and Eli Lilly; fees for consulting or advisory roles from Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Incyte, Regeneron, MorphoSys, Novartis, Sobi, and Eli Lilly; fees for participation in speakers\u2019 bureaus from Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences, Novartis, Gilead, Incyte, Pfizer, MorphoSys, Sobi, and Eli Lilly; and research funding from Roche\/Genentech, Janssen, Celltrion, MSD, Pfizer, Amgen, and Bayer. Nora Hennies, Sabrina Khageh Hosseini, Sebastian B\u00f6lz, Derya Bocuk, J\u00fcrgen Zschocke, and Stefan Wilhelm are employees and minor shareholders of Eli Lily and Company. Okan Zaba is a former employee of Eli Lily and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}